Teriflunomide in Multiple Sclerosis: An Update

    Aaron Miller
    Studysummary This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on futuremedicine.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Pooled Safety and Tolerability Data from Four Placebo-Controlled Teriflunomide Studies and Extensions Multiple Sclerosis and Related Disorders · 2015
    2. Teriflunomide and Its Mechanism of Action in Multiple Sclerosis Drugs · 2014